Carbetocin

Ferring's total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur ® Continued ramp-up in the US for Adstiladrin ® , our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver Commitment to sustainability demonstrated by SBTi approval of our targets to reduce greenhouse gas emissions, and by our programme to reduce maternal deaths in low- and lower middle-income countries SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring today published its 2025 Annual Report and Sustainability Report . The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur ® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin ® (nadofaragene firadenovec-vncg). Operating expenses were contained to an increase of €61 million year-on-year (i.e. +5% at AER and +7% at CER), and this includes significant non-recurring items (notably impairment charges and restructuring provisions). Underlying operating expenses remained well-controlled, with increased investments targeted to support the growth of Adstiladrin and other opportunities. Thus, operating profit for the year reached €167 million, a decrease of -€24 million (‑13%) versus the prior year at AER, while remaining flat at CER - with the difference being driven by the weaker US dollar. Following a focus on improving cash conversion after several heavy investments, free cash flow generation approached neutral despite currency headwinds from the weaker US dollar. This represents a substantial improvement compared to the previous year, and a significant step towards sustainable cash generation. Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, said: “This was a pivotal year as we continued evolving our business to become stronger, more agile and more resilient, and importantly we got back to free cash flow neutral. Moreover, in 2025, we introduced an enterprise model designed to create greater value for patients and customers while supporting sustainable growth. This reflects our long-term commitment to serving patients’ need, and fostering an environment where people can learn, grow and perform at their best.” Ferring has always conducted business responsibly by seeking to protect the environment, create value for society, and uphold our high standards of ethics and governance. In 2025, we passed a major milestone when our targets for reducing greenhouse gas (GHG) emissions were approved by the Science Based Targets initiative (SBTi). This globally recognised standard ensures corporate goals are aligned with international climate policy. During the year, we succeeded in reducing our Scope 1 and 2 GHG emissions by 4.3% and Scope 3 emissions by 19%. Access to affordable healthcare is embedded in Ferring’s purpose and strategic priorities. The Project Family™: Safe Birth initiative aims to reduce maternal deaths in low- and lower middle-income countries by enabling wider access to Carbetocin Ferring (carbetocin, room-temperature stable formulation). In 2025, we worked with partners to supply around 1.7 million doses of this life-saving medicine at an affordable access price, while gaining further approvals in seven low- and lower middle-income countries. About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Learn more at , or connect with us on LinkedIn , Instagram and YouTube . Contacts For more information, please contact Carine Julen Senior Manager, Corporate Communications & Public Affairs carine.julen@ferring.com

圣诺生物（688117.SH）：多肽领域的领航先锋 在医药行业的璀璨星空中，圣诺生物（688117.SH）犹如一颗耀眼的明星，凭借其在多肽领域的卓越成就，成为全球多肽药物研发与生产的重要力量。自2001年成立以来，圣诺生物始终专注于多肽原料药和制剂产品的研发、生产与销售，同时积极拓展多肽创新药药学研究服务、定制生产服务以及技术转让服务等业务，为全球医药产业的发展注入了强大动力。 多元产品矩阵，满足多领域需求 圣诺生物构建了丰富多元的产品矩阵，涵盖多肽原料药和多肽制剂两大核心板块。在多肽原料药领域，公司已掌握21个品种的规模化生产技术，其中14个品种在国内取得生产批件或激活备案，11个品种获得美国DMF备案且处于激活状态。这些原料药产品不仅在国内市场占据重要地位，还成功出口至欧美、印度、韩国等国际市场，终端客户包括费森尤斯、阿拉宾度、迈兰等国内外知名医药企业。 在多肽制剂领域，公司延伸开发了多个制剂品种，并在国内取得了多个生产批件。产品涵盖免疫、消化道、抗病毒、妇产科、糖尿病、心脑血管、罕见病、骨科等多个治疗领域，为患者提供了多样化的治疗选择。其中，注射用恩夫韦肽和卡贝缩宫素注射液为国内首仿多肽药物，彰显了公司在多肽制剂研发方面的强大实力。 畅销产品：司美格鲁肽原料药，引领市场潮流 司美格鲁肽原料药是圣诺生物的当之无愧的畅销产品，在全球多肽原料药市场中占据着举足轻重的地位。近年来，随着全球GLP-1类药物市场的爆发式增长，司美格鲁肽作为该领域的明星药物，市场需求持续激增。弗若斯特沙利文的预测数据显示，全球GLP-1类药物市场规模有望从2025年的960亿美元增长至2030年的1419亿美元，其间年复合增长率超过8%，市场增长潜力巨大。 圣诺生物的司美格鲁肽原料药凭借其卓越的品质和稳定的供应能力，赢得了国内外客户的广泛认可。公司司美格鲁肽原料药已于2024年成功获得美国FDA备案，并通过韩国MFDS认证，为其产品大规模进军海外市场扫清了关键的监管障碍。在2025年半年报中，公司明确提及当期营业收入和归母净利润的大幅增长，主要得益于司美格鲁肽原料药境外销售额的大幅攀升。 核心技术支撑，铸就竞争壁垒 圣诺生物在多肽领域拥有一系列自主知识产权的核心技术，形成了坚实的技术壁垒。公司具备多肽原料药和制剂的全流程研发管线和全产业链平台，能够为多肽创新药和仿制药提供从工艺路线设计、小试、中试、工艺验证到质量研究等药学研究服务，以及药物研发及商业化生产所需原料药、制剂产品的全链条定制生产服务，涵盖从药物发现、临床前研究到临床试验和上市销售的完整药物开发周期。 在多肽合成和修饰技术方面，公司不断创新，掌握了先进的化学合成法和固相合成法等核心技术，能够高效、稳定地合成各种复杂的多肽分子。同时，公司还注重非专利技术的积累，拥有大量的药品生产配方及相应的生产加工工艺，为产品的质量和稳定性提供了有力保障。 此外，圣诺生物积极拥抱新技术，将AI技术应用于多肽研发领域。公司联合浙江大学衢州研究院成立“美容肽创新联合研发中心”，以“环肽技术 + AI赋能”双引擎驱动行业变革。通过AI预测平台构建，公司能够快速筛选出高活性、高稳定性的候选分子，大幅缩短研发周期；基于自研数据库DermaPepDB覆盖超10000组靶点数据，靶点解析准确率较传统方法提升85%，筛选效率提升超百倍，为美容肽的精准设计与靶点预测提供了有力支持。 全方位服务，赢得客户信赖 圣诺生物注重为客户提供全方位、一站式的服务，从研发、生产到售后，都以客户需求为导向，为客户提供优质、高效的服务。 在研发阶段，公司与客户紧密合作，深入了解客户需求，为客户提供定制化的产品解决方案。根据客户对药物性能、疗效和安全性的不同要求，研发团队能够迅速调整研发策略，开展针对性的研究工作，确保开发出的产品能够满足客户的个性化需求。 在生产过程中，公司建立了严格的质量控制体系，从原材料采购到产品出厂，每一个环节都经过严格检测和监控，确保每一批产品都符合高质量标准。公司还拥有先进的生产设备和现代化的生产基地，能够实现多肽原料药和制剂的大规模、稳定生产，为客户提供充足的产品供应。 在售后服务方面，公司拥有一支专业的技术团队，能够及时响应客户的咨询和问题。无论是产品使用过程中的技术指导，还是产品质量的反馈处理，技术团队都能迅速为客户提供解决方案，让客户无后顾之忧。 展望未来，续写辉煌篇章 随着全球医药产业的持续快速发展，多肽药物市场迎来了前所未有的发展机遇。圣诺生物将继续秉承创新理念，加大研发投入，不断提升产品性能和技术水平。在多肽原料药领域，公司将进一步扩大产能，提高产品质量，满足市场对高品质多肽原料药的需求；在多肽制剂领域，公司将加快新产品的研发和上市步伐，拓展产品治疗领域，为患者提供更多更好的治疗选择。 同时，圣诺生物将积极拓展国际市场，加强与全球知名医药企业的合作，提升公司的国际影响力。通过不断优化产品和服务，满足全球客户的需求，圣诺生物有望在多肽领域续写辉煌篇章，为全球医药产业的发展做出更大的贡献。